NOX noxopharm limited
Add to My Watchlist 0.00% ! 9.8¢

News: NOX Noxopharm Phase I Clinical Trial Shows Anti-Inflammatory Response In Covid-19 Patients

  1. Hot News
    193,698 Posts.
    lightbulb Created with Sketch. 2825
    clock Created with Sketch.
    25/08/21
    23:40
    Post #: 55575494

    Aug 25 (Reuters) - Noxopharm Ltd (NOX) :

    • NOXOPHARM PHASE I CLINICAL TRIAL SHOWS ANTI-INFLAMMATORY RESPONSE IN COVID-19 PATIENTS
    • NOXOPHARM - STARTED DISCUSSIONS TO ADD VEYONDA TO ONE OF GLOBAL CLINICAL TRIAL PROGRAMS TO IDENTIFY EFFECTIVE ANTI-INFLAMMATORY THERAPIES IN COVID-19
    Likes Created with Sketch. 2  Upvote
    lightbulb Created with Sketch.  Great analysis
    Stroke 3 Created with Sketch. Comments Created with Sketch. Reply

  2. Top Stories

 

Featured News

NEWS Outstanding thick high-grade gold revealed in first Greenewood assays
right-arrow Created with Sketch.
NEWS The 4 sectors poised to benefit from Australia's immigration wave
right-arrow Created with Sketch.
NEWS Drilling to commence at FAU’s Gimlet high-grade gold project following approvals
right-arrow Created with Sketch.
NEWS How to handle a financial crisis and turn setbacks into setups
right-arrow Created with Sketch.
NEWS New targets and high-grade intercepts drive Bullabulling drill expansion
right-arrow Created with Sketch.
NEWS View the latest ASX market news here
right-arrow Created with Sketch.
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
Add to My Watchlist
(20min delay)
Last
9.8¢ 		Change
0.000(0.00%) 		Mkt cap ! $28.63M
Open High Low Value Volume
9.7¢ 9.8¢ 9.5¢ $15.43K 159.9K

Buyers (Bids)

No. Vol. Price($)
1 47773 9.3¢
 

Sellers (Offers)

Price($) Vol. No.
9.8¢ 47899 1
View Market Depth
Last trade - 16.10pm 12/09/2025 (20 minute delay) ?
NOX (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.